Cytotoxins and immunotoxins for cancer therapy : clinical applications
著者
書誌事項
Cytotoxins and immunotoxins for cancer therapy : clinical applications
CRC Press, c2005
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Recent advances in cytotoxins and immunotoxins are accelerating our understanding of cancer and leading to more effective therapeutic treatments. Although a large number of articles have been published on these cytotoxins and immunotoxins, this important information has yet to be compiled into one comprehensive resource.
For the first time, Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications presents state-of-the-art information on various cytotoxins and immunotoxins in a single, highly anticipated publication. The editors bring together leading researchers to summarize their work and discuss clinical trial data concerning some of the most widely studied tumors. The book describes Pseudomonas exotoxin (PE)-based immunotoxins and presents the latest results from clinical trials for the treatment of recurrent glioblastoma and other human cancers. It reviews the role of ricin-based immunotoxins for the treatment of lymphoma, explores several DT-based immunotoxins, and details the preclinical and clinical development of the first FDA-approved cytotoxin.
With a focus on clinical developmental approaches to the use of cytotoxins and immunotoxins, this book discusses exciting possibilities for cancer therapy. It is a valuable resource for scientists, researchers, and clinicians involved in the development of new treatments that can help keep cancer under control, and may ultimately lead to a cure.
目次
Preface: An Overview of Immunotoxins and Cytotoxins in Clinical Trials. PART 1. PSEUDOMONAS EXOTOXIN (PE)-BASED IMMUNOTOXINS/CYTOTOXINS. Targeting of Pseudomonas Exotoxin-based Immunotoxins to Hematologic Malignancies. Interleukin-4-targeted Cytotoxin for Recurrent Glioblastoma Therapy. Interleukin-13 Receptors and Development of IL-13-Pseudomonas Exotoxin for Human Cancer Therapy. PART 2. RICIN-BASED IMMUNOTOXINS/CYTOTOXINS. Ricin Immunotoxins in Lymphomas. PART 3. DIPHTHERIA TOXIN (DT)-BASED IMMUNOTOXINS/CYTOTOXINS. Diphtheria-based Immunotoxins: Targeting Overexpressed Interleukin-13 Receptor and Urokinase-type Plasminogen Activator Receptor on Glioblastoma Multiforme. DAB389IL-2 (Ontak): Development and Therapeutic Applications. Transferrin Diphtheria Toxin for Brain Tumor Therapy. GM-CSF Receptor Targeted Therapy of Human Leukemia. VEGF-diphtheria toxin for Targeting of Tumor Blood Vessels. PART 4. MISCELLANEOUS. cBR-96-doxorubicin (SGN-15) for Metastatic Breast Cancer Therapy. Anti-CD33 Calicheamicin Immunoconjugate Therapy of Acute Myeloid Leukemia.
「Nielsen BookData」 より